← Leaderboards
Matthew L Meyerson
Brigham And Women'S Hospital
$42,525,014
Attributed
$52,745,759
Total exposure
13
Grants
11
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $6.1M · FY2005–25$10M$7.5M$5M$2.5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$70,559,218 · 14
By mechanism
U24$24,732,941 · 2
P01$21,820,105 · 5
R35$11,378,575 · 1
R01$9,892,101 · 3
RC2$1,551,550 · 1
P50$1,183,946 · 1
Top collaborators
- Michael J Eck11 shared
- Stacey Gabriel9 shared
Most similar at Brigham And Women'S Hospital
Same institution · by research overlap
- Mark A. Rubin$21,732,421
- Raul San Jose Estepar$11,331,173
- Joel Voldman$6,954,416
- Ron Firestein$142,358
- Eunjung Alice Lee$9,641,765
Others in their field
Top investigators on “Malignant Neoplasm Of Lung”
- David Heimbrook · Leidos Biomedical Research, Inc.$349,639,893
- Richard K. Wilson · Washington University$202,666,376
- Walter John Curran · Thomas Jefferson University$94,674,902
- Jan C Buckner · Mayo Clinic Coll Of Medicine, Rochester$61,410,512
- Norman Wolmark · Nsabp Foundation, Inc.$54,610,124
- Leonard Freedman · Leidos Biomedical Research, Inc.$50,919,602
Research focus
Malignant Neoplasm Of LungMalignant NeoplasmsMutationEpidermal Growth Factor ReceptorGenomicsBaseLeadNon-Small-Cell Lung CarcinomaResearch PersonnelCancer TherapyPhosphotransferasesKinase InhibitorTargeted TreatmentGenomeProgramsInhibitor/AntagonistStructureCancer EtiologyMutantTherapeutic TargetPathogenesisResistanceLung AdenocarcinomaCessation Of Life
Grant awards (89)
Lung Adenocarcinoma: From Genome Alterations to Therapeutic Discovery$1,044,600
R35 · FY2025 · CA · contact PI
Lung Adenocarcinoma: From Genome Alterations to Therapeutic Discovery$992,188
R35 · FY2024 · CA · contact PI
Lung Adenocarcinoma: From Genome Alterations to Therapeutic Discovery$1,023,709
R35 · FY2023 · CA · contact PI
Lung Adenocarcinoma: From Genome Alterations to Therapeutic Discovery$1,023,709
R35 · FY2022 · CA · contact PI
Inhibitor-sensitive and -resistant EGFR mutants from lung cancer and glioblastoma$260,727
R01 · FY2022 · CA
NKX2-1 Enhancer Amplification and Lineage Addiction in Lung Adenocarcinoma$94,095
R35 · FY2022 · CA · contact PI
Protein Kinase Therapeutic Targets for Non-Small Cell Lung Carcinoma$1,846,173
P01 · FY2021 · CA · contact PI
Lung Adenocarcinoma: From Genome Alterations to Therapeutic Discovery$1,068,000
R35 · FY2021 · CA · contact PI
Project 3: Targeting transcriptional mechanisms of therapeutic resistance in non-small cell lung cancer.$348,207
P01 · FY2021 · CA · contact PI
Core D: Program Administration$126,586
P01 · FY2021 · CA · contact PI
Inhibitor-sensitive and -resistant EGFR mutants from lung cancer and glioblastoma$108,012
R01 · FY2021 · CA
Protein Kinase Therapeutic Targets for Non-Small Cell Lung Carcinoma$1,846,173
P01 · FY2020 · CA · contact PI
How do genome alterations cause human lung cancer?$1,027,500
R35 · FY2020 · CA · contact PI
Inhibitor-sensitive and -resistant EGFR mutants from lung cancer and glioblastoma$374,063
R01 · FY2020 · CA
Project 3: Targeting transcriptional mechanisms of therapeutic resistance in non-small cell lung cancer.$348,207
P01 · FY2020 · CA · contact PI
Core D: Program Administration$126,586
P01 · FY2020 · CA · contact PI
Protein Kinase Therapeutic Targets for Non-Small Cell Lung Carcinoma$1,847,127
P01 · FY2019 · CA · contact PI
How do genome alterations cause human lung cancer?$996,674
R35 · FY2019 · CA · contact PI
Inhibitor-sensitive and -resistant EGFR mutants from lung cancer and glioblastoma$362,840
R01 · FY2019 · CA
Core D: Program Administration$126,587
P01 · FY2019 · CA · contact PI
Protein Kinase Therapeutic Targets for Non-Small Cell Lung Carcinoma$1,846,173
P01 · FY2018 · CA · contact PI
How do genome alterations cause human lung cancer?$1,027,500
R35 · FY2018 · CA · contact PI
Inhibitor-sensitive and -resistant EGFR mutants from lung cancer and glioblastoma$374,063
R01 · FY2018 · CA
Core D: Program Administration$126,586
P01 · FY2018 · CA · contact PI
Protein Kinase Therapeutic Targets for Non-Small Cell Lung Carcinoma$1,846,248
P01 · FY2017 · CA · contact PI
How do genome alterations cause human lung cancer?$1,027,500
R35 · FY2017 · CA · contact PI
Inhibitor-sensitive and -resistant EGFR mutants from lung cancer and glioblastoma$374,063
R01 · FY2017 · CA
Core D: Program Administration$126,586
P01 · FY2017 · CA · contact PI
Protein Kinase Therapeutic Targets for Non-Small Cell Lung Carcinoma$1,747,745
P01 · FY2016 · CA · contact PI
How do genome alterations cause human lung cancer?$1,027,500
R35 · FY2016 · CA · contact PI
DDR2 kinase inhibition in squamous cell lung carcinomas$395,684
P01 · FY2016 · CA · contact PI
Inhibitor-sensitive and -resistant EGFR mutants from lung cancer and glioblastoma$326,813
R01 · FY2016 · CA
Genome Characterization Center (GCC)$188,131
U24 · FY2016 · CA · contact PI
Administration$157,447
P01 · FY2016 · CA · contact PI
Protein Kinase Therapeutic Targets for Non-Small Cell Lung Carcinoma$1,747,745
P01 · FY2015 · CA · contact PI
How do genome alterations cause human lung cancer?$1,025,600
R35 · FY2015 · CA · contact PI
DDR2 kinase inhibition in squamous cell lung carcinomas$395,684
P01 · FY2015 · CA · contact PI
Genome Characterization Center (GCC)$364,797
U24 · FY2015 · CA · contact PI
Inhibitor-sensitive and -resistant EGFR mutants from lung cancer and glioblastoma$326,813
R01 · FY2015 · CA
Administration$157,447
P01 · FY2015 · CA · contact PI
Protein Kinase Therapeutic Targets for Non-Small Cell Lung Carcinoma$1,695,312
P01 · FY2014 · CA · contact PI
Genome Characterization Center (GCC)$947,907
U24 · FY2014 · CA · contact PI
NKX2-1, A Candidate Lineage Survival Oncogene in Lung Adenocarcinoma$411,644
R01 · FY2014 · CA · contact PI
DDR2 kinase inhibition in squamous cell lung carcinomas$383,814
P01 · FY2014 · CA · contact PI
Inhibitor-sensitive and -resistant EGFR mutants from lung cancer and glioblastoma$317,009
R01 · FY2014 · CA
Administration$152,722
P01 · FY2014 · CA · contact PI
Genome Characterization Center (GCC)$3,035,866
U24 · FY2013 · CA · contact PI
Protein Kinase Therapeutic Targets for Non-Small Cell Lung Carcinoma$1,506,401
P01 · FY2013 · CA · contact PI
NKX2-1, A Candidate Lineage Survival Oncogene in Lung Adenocarcinoma$398,913
R01 · FY2013 · CA · contact PI
Inhibitor-sensitive and -resistant EGFR mutants from lung cancer and glioblastoma$307,204
R01 · FY2013 · CA
DDR2 kinase inhibition in squamous cell lung carcinomas$236,209
P01 · FY2013 · CA · contact PI
Administration$201,926
P01 · FY2013 · CA · contact PI
Genome Characterization Center (GCC)$2,562,032
U24 · FY2012 · CA · contact PI
Protein Kinase Therapeutic Targets for Non-Small Cell Lung Carcinoma$1,884,362
P01 · FY2012 · CA · contact PI
DDR2 kinase inhibition in squamous cell lung carcinomas$426,614
P01 · FY2012 · CA · contact PI
NKX2-1, A Candidate Lineage Survival Oncogene in Lung Adenocarcinoma$424,375
R01 · FY2012 · CA · contact PI
Inhibitor-sensitive and -resistant EGFR mutants from lung cancer and glioblastoma$326,813
R01 · FY2012 · CA
CD: Genomics and Bioinformatics$326,716
P50 · FY2012 · CA · contact PI
Administration$169,754
P01 · FY2012 · CA · contact PI
Genome Characterization Center (GCC)$2,621,239
U24 · FY2011 · CA · contact PI
NKX2-1, A Candidate Lineage Survival Oncogene in Lung Adenocarcinoma$424,375
R01 · FY2011 · CA · contact PI
CD: Genomics and Bioinformatics$307,714
P50 · FY2011 · CA · contact PI
Genome Characterization Center (GCC)$2,754,287
U24 · FY2010 · CA · contact PI
An infrastructure for cancer virus discovery from next-generation sequencing data$786,413
RC2 · FY2010 · CA · contact PI
Genome Characterization Center (GCC)$608,811
U24 · FY2010 · CA · contact PI
NKX2-1, A Candidate Lineage Survival Oncogene in Lung Adenocarcinoma$434,583
R01 · FY2010 · CA · contact PI
Inhibitor-sensitive and -resistant EGFR mutants from lung cancer and glioblastoma$338,027
R01 · FY2010 · CA · contact PI
CD: Genomics and Bioinformatics$324,085
P50 · FY2010 · CA · contact PI
Genome Characterization Center (GCC)$3,900,000
U24 · FY2009 · CA · contact PI
An infrastructure for cancer virus discovery from next-generation sequencing data$765,137
RC2 · FY2009 · CA · contact PI
Center for Cancer Genome Characterization$611,323
U24 · FY2009 · CA · contact PI
Inhibitor-sensitive and -resistant EGFR mutants from lung cancer and glioblastoma$333,806
R01 · FY2009 · CA · contact PI
CD: Genomics and Bioinformatics$123,883
P50 · FY2009 · CA · contact PI
Center for Cancer Genome Characterization$1,197,676
U24 · FY2008 · CA · contact PI
Center for Cancer Genome Characterization$1,189,103
U24 · FY2008 · CA · contact PI
Elucidating the somatic genetics of prostate cancer$432,151
R01 · FY2008 · CA · contact PI
Inhibitor-sensitive and -resistant EGFR mutants from lung cancer and glioblastoma$326,489
R01 · FY2008 · CA · contact PI
CD: Genomics and Bioinformatics$101,548
P50 · FY2008 · CA · contact PI
Center for Cancer Genome Characterization$2,363,991
U24 · FY2007 · CA · contact PI
Elucidating the somatic genetics of prostate cancer$430,091
R01 · FY2007 · CA · contact PI
Inhibitor-sensitive and -resistant EGFR mutants from lung cancer and glioblastoma$325,709
R01 · FY2007 · CA · contact PI
Center for Cancer Genome Characterization$2,387,778
U24 · FY2006 · CA · contact PI
Elucidating the somatic genetics of prostate cancer$431,688
R01 · FY2006 · CA · contact PI
Inhibitor-sensitive and -resistant EGFR mutants from lung cancer and glioblastoma$325,631
R01 · FY2006 · CA · contact PI
Elucidating the somatic genetics of prostate cancer$417,172
R01 · FY2005 · CA
Cancer Virus Discovery by Computational Subtraction$324,868
R01 · FY2005 · CA
Cancer Virus Discovery by Computational Subtraction$326,132
R01 · FY2004 · CA
Cancer Virus Discovery by Computational Subtraction$328,027
R01 · FY2003 · CA
Virus discovery in cutaneous T cell lymphoma$0
P30 · FY2002 · AR